SCHEMBL1480693

SCHEMBL1480693

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1cc(-c2ccc(OCCCC(=O)OC)cc2)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
CNR1 P21554 5/20 0.37
PDE3B Q13370 5/20 0.36
PDE3A Q14432 5/20 0.36
P2RY12 Q9H244 4/20 0.36
PDE2A O00408 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
DHODH Q02127 1/20 0.34
PABPC1 P11940 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KCNA3 P22001 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480691 1.00 MAPT (0.39) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481076 0.95 MAPT (0.39) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481072 0.95 MAPT (0.39) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1482184 0.92 FFAR4 (0.43) CNR1CYP3A4FFAR1FFAR4DHODH
SCHEMBL1482188 0.92 FFAR4 (0.43) CNR1CYP3A4FFAR1FFAR4DHODH
SCHEMBL12754214 0.92 MAPT (0.43) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481218 0.90 MAPT (0.42) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481219 0.90 MAPT (0.42) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481004 0.89 MAPT (0.38) MAPTCNR1PDE3BPDE3AP2RY12
SCHEMBL1481006 0.89 MAPT (0.38) MAPTCNR1PDE3BPDE3AP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885PDE3B 183/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885PDE3B 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.